



NEWS

Media Contact: Susan Falk, 414.232.2562
PubRel@Rondaxe.com

RONDAXE ENTERPRISES NAMES KENTON SHULTIS CEO

Former President Jeff Evans, Ph.D., to Launch Oncoholdings

SYRACUSE, N.Y. (Oct. 1, 2010) – Rondaxe Enterprises, a drug development consulting company, has announced the appointment of Kenton Shultis to Chief Executive Officer. Mr. Shultis takes over the helm as Dr. Jeffrey Evans leaves the President's post to start a new company, Oncoholdings Inc.

Prior to being named Rondaxe Enterprises' CEO, Mr. Shultis was responsible for the company's Software Development and Pharma Consulting groups. In that capacity, he oversaw a myriad of services including product development planning, quality systems design, API and formulation COGs evaluations, technology transfer support, process and facility engineering and supplier negotiations.

"Ken's leadership at Rondaxe and his deep understanding of the business and the industry equips him to grow the company, its clients and people. I am most grateful to Ken and Rondaxe to afford myself the opportunity to launch Oncoholdings, and I look forward to a continued relationship with Rondaxe as a strategic vendor to my new company," said Dr. Evans.

Prior to joining Rondaxe in 2008, Mr. Shultis was Vice President of Operations and General Manager of Organichem for AMRI after founding American Advanced Organics where he served as President for two years. He spent 14 years at Bristol-Myers Squibb as Director of Pilot Plant Development where he led several multiple site plant introduction programs. Mr.

Shultis also worked in Process R&D at Merck and in Fermentation Development at Abbott Laboratories.

Dr. Evans has based Oncoholdings in Syracuse, N.Y., with offices in San Francisco, Calif., and Scottsdale, Ariz. Oncoholdings is focused on the acquisition and development of promising preclinical and early clinical anti-cancer agents. Dr. Evans, is joined by a team of industry heavyweights including: Benjamin P. Chen, Ph.D.; Jeffrey R. Latts, M.D.; Stephen Gately, Ph.D.; Daniel D. Von Hoff, M.D., F.A.C.P.; Randall R. Lund; Allan Shaw; and Wilhelm Stahl, Ph.D., who is also president of Rondaxe Deutschland, OHG. More information about Oncoholdings can be found at www.Oncoholdings.com

About Rondaxe Enterprises

Rondaxe Enterprises is a unique company providing a suite of services that combines expert drug development consulting, in-depth project management leadership, software applications and virtual business development designed specifically for emerging pharmaceutical and biotech companies. Rondaxe is led by four managing members, a team of experienced industry executives and more than 50 senior advisors, most of whom have 15-30 plus years of industry experience, with a vision and an unflinching dedication to clients' success. Founded in 2003, Rondaxe has enjoyed steady growth based on a proven track record in delivering results, establishing solid relationships with customers, and a strong commitment to expand skills and product offerings as customer's needs expand. For more information, visit www.rondaxe.com

#####